Targeted anticancer therapies exploit genetic and biochemical alterations unique to malignant cells, and administering combinations of targeted drugs based on the constellation of specific mutations present in an individual tumour is a rational strategy for treating advanced cancers. In T-ALL, mutations that deregulate Notch1 and Ras/PI3K signalling occur in 60% and 55% of patients, respectively [1] [2] [3] . Recent data indicate that PI3K pathway activation is associated with aggressive biological features, drug resistance and poor prognosis in T-ALL [4] [5] [6] [7] [8] [9] . GDC-0941 is a potent PI3K inhibitor that is rapidly advancing in clinical development 10 . We observed downregulation of activated Notch1 signalling and reduced Myc expression in T-ALL cell lines and primary leukaemias that became resistant to GDC-0941 in vitro and in vivo. These data implicate PI3K as a dominant oncogenic driver pathway in T-ALL, and indicate that combining targeted anticancer drugs may have unanticipated effects on clonal dynamics and inadvertently promote the outgrowth of resistant cells.
Loss of Notch1 with PI3K inhibitor resistance
T-ALLs were generated by performing retroviral insertional mutagenesis (RIM) in wild-type (Kras WT ) and Mx1-cre, Kras LSL-G12D (Kras G12D ) mice 11 , and by expressing mutant Kras in a transduction/transplantation system 12 . These primary T-ALLs are characterized by diverse retroviral integrations, heterogeneous biochemical activation of the Raf/MEK/ ERK and PI3K/Akt effector pathways, and secondary acquisition of somatic Notch1 mutations (Extended Data Fig. 1a ). Cell lines generated from murine T-ALLs are uniformly sensitive to PI3K inhibition 11, 12 . To uncover potential mechanisms of acquired resistance, we exposed T-ALL cell line E2 (ref. 12) to increasing concentrations of GDC-0941 (ref. 10) . In comparison to the parental E2 cell line, all three resistant lines (E2-R3, E2-R5 and E2-R6) proliferated in a tenfold higher concentration of GDC-0941 as assessed by cell numbers (Fig. 1a) and 5-bromodeoxyuridine (BrdU) labelling ( Fig. 1b and Extended Data Fig. 2a) . Resistant E2 cells also required higher drug concentrations to efficiently induce cleaved caspase 3 and inhibit higher levels of phosphorylated Akt (pAkt) (Fig. 1c, d ).
Unexpectedly, resistant E2 clones downregulated the expression of activated Notch intracellular domain (NICD) proteins and were insensitive to compound E, a potent c-secretase inhibitor (GSI) that blocks an essential enzymatic cleavage step for generating NICD 3 ( Fig. 1e, f) .
Efficacy of PI3K and MEK inhibitors in vivo
Leukaemias generated by RIM recapitulate the genetic heterogeneity seen in advanced human cancers, and transplantation into recipient mice provides a flexible system for investigating therapeutic responses and elucidating mechanisms of drug resistance (Extended Data Fig. 1b) . Advantages of this approach include: (1) primary cancers are treated in immunocompetent mice; (2) retroviral integration patterns can be used to track the emergence of drug-resistant clones; and (3) relapsed leukaemia cells can be re-transplanted to verify intrinsic resistance and test alternative therapies 13 . We transplanted 6 Kras WT and 15 Kras G12D TALLs (Extended Data Table 1 ) into 168 recipients (8 per leukaemia) and randomly assigned these mice to receive GDC-0941 or control vehicle (n 5 5 and 3, respectively). Mice were treated for 8 weeks or until they required euthanasia due to progressive leukaemia. The maximally tolerated dose (MTD) of GDC-0941 is 125 mg kg 21 day 21 in sublethally irradiated mice and results in drug exposures sufficient to effectively inhibit PI3K for .8 h (Extended Data Fig. 3 ). Overall, treatment at this dose significantly extended the survival of recipients transplanted with Kras WT , but not Kras
G12D
, leukaemias (Fig. 2a, b ). An analysis of individual primary leukaemias showed that 3 of 6 Kras WT and 4 of 15 Kras T-ALLs responded to GDC-0941 (Extended Data Table 1 ). Importantly, these heterogeneous and transient in vivo responses contrast with the uniform in vitro sensitivity of T-ALL cell lines to PI3K inhibition 11, 12 . The Raf/MEK/ERK pathway is a major effector of oncogenic Ras signalling, and combining MEK and PI3K inhibitors is efficacious in murine Kras-driven tumours 14 . We previously administered PD0325901 (PD901), a potent and selective MEK inhibitor T-ALLs compared to the control vehicle (Fig. 2a, b) . Examining the individual Kras G12D leukaemias showed that the GDC-0941/PD901 combination markedly extended the survival of recipients transplanted with T-ALLs that were initially sensitive to GDC-0941, and was also efficacious in seven leukaemias that were unresponsive to GDC-0941 alone (Extended Data Table 1 ).
Drug-resistant clones downregulate NICD
Despite continuous treatment, recipient mice invariably died of refractory T-ALL, which showed similar morphological and immunophenotypic features to the respective parental leukaemia (Extended Data Fig. 4) . We transplanted leukaemia cells from mice that succumbed after initially responding to either GDC-0941 (n 5 5) or to the GDC-0941/PD901 combination (n 5 5) into secondary recipients, retreated them, and found that none responded to treatment in vivo (Fig. 2c) . On the basis of these functional data, we hereafter refer to leukaemias that emerged after an initial response to targeted agents as 'resistant'. We analysed retroviral integrations to determine whether resistant T-ALLs exhibit clonal evolution. Southern blotting with a virus-specific probe revealed shared restriction fragments as well as one or more novel bands in many resistant leukaemias (Fig. 2d) , and shotgun cloning of viral integration sites demonstrated insertions that were unique to or highly enriched in different resistant subclones (Extended Data Table 2 ). Clonal evolution was observed in 10 of 14 responsive T-ALLs, but not in the 7 primary T-ALLs that displayed de novo drug resistance (Extended Data Table 1) .
Reduced NICD expression in GDC-0941-resistant cell lines (Fig. 1e ) led us to examine Notch1 signalling in resistant T-ALLs that emerge in vivo. Indeed, western blot analysis revealed greatly reduced NICD expression in 19 of 31 (61%) independent resistant clones derived from 8 parental T-ALLs (Fig. 3a and Extended Data Fig. 5a ). Resistant T-ALLs and resistant cells at 1 mM marked with an asterisk (two-sided t-test; b, R3, R5, P , 0.0001; c, R3, R5, P 5 0.0004). d, Western blotting 20 min after GDC-0941 (0941) exposure shows that elevated pAkt S473 levels are suppressed in resistant lines by higher drug concentrations. e, f, Activated Notch1 (NICD) is reduced in resistant T-ALL cells (e), which are also resistant to compound E (f; dotted lines). The experiments in a-e were performed three times, and in f in duplicate.
Survival of Kras G12D T-ALLs (Fig. 3b) . Interestingly, Nrarp and Hes1 transcript levels were stable or higher in resistant T-ALLs, a finding independently verified by quantitative realtime PCR (Fig. 3b and data not shown). This observation suggests that Nrarp and Hes1 expression is uncoupled from Notch1 pathway activation in resistant T-ALLs.
To determine whether resistant leukaemias are less dependent on Notch1 signalling, we exposed primary T-ALL cells to compound E ex vivo. Multiple resistant clones isolated from two parental T-ALLs showed reduced sensitivity to GSI treatment than the corresponding parental leukaemia ( Fig. 3c and Extended Data Fig. 5b ). We also cultured parental and resistant leukaemia cells in a range of GDC-0941 concentrations with or without 0.1 mM of compound E. Whereas compound E cooperated with GDC-0941 to reduce the growth of parental T-ALLs, GSI treatment had no additive effects in the resistant clones ( Fig. 3d and Extended Data Fig. 5c ).
We sequenced Notch1 and found that mutations identified in the parental T-ALLs were unexpectedly absent or detected at greatly reduced levels in six independent resistant leukaemias derived from four parental T-ALLs (Fig. 3e ). In addition, retroviral integrations within the Notch pathway genes Notch1, Aph1 (also known as Alph1) and Dtx1 were highly enriched in three resistant leukaemias with reduced NICD/Myc expression, strongly implicating insertional mutagenesis as an alternative mechanism of reduced Notch1 signalling (Extended Data Fig. 5d and Extended Data Table 2 ). Importantly, resistant leukaemias with decreased or absent NICD and Myc expression were recovered from recipients treated with either GDC-0941 or with the GDC-0941/PD901 combination, suggesting that P13K inhibition imposes selective pressure to downregulated oncogenic Notch1 signalling.
Activated Notch1 supresses PI3K signalling
To address why Notch1 mutations that confer a clonal growth advantage during leukaemogenesis might unexpectedly 'switch' to become deleterious when PI3K is inhibited therapeutically, we examined PI3K signalling in resistant T-ALLs with loss of NICD expression. Each parental and resistant T-ALL displayed a consistent pattern of protein phosphorylation in independent recipient mice ( Fig. 4a ). Resistant leukaemias generally had reduced PTEN expression and biochemical evidence of PI3K pathway activation-characterized by elevated pAkt and pS6 levelsrelative to the respective parental T-ALL (Fig. 4a) . Some resistant leukaemias also showed increased pERK (Fig. 4a) . Whereas GDC-0941 treatment markedly reduced BrdU incorporation by parental T-ALLs in vivo, resistant leukaemias continued to proliferate ( Fig. 4b and Extended Data Fig. 2b ). Parental T-ALL cells isolated from recipient mice expressed high levels of cleaved caspase 3 after overnight culture, which were further induced by exposure to GDC-0941 (Fig. 4c ). Basal cleaved caspase 3 levels were remarkably lower in resistant T-ALLs, but were induced by GDC-0941 exposure (Fig. 4c) . Importantly, induction of cleaved caspase 3 in resistant T-ALLs correlated with the 5-50-fold higher concentrations of GDC-0941 required to suppress pAkt ( Fig. 4d and Extended Data Fig. 6 ).
In T-ALL and during thymic development Notch1 upregulates Hes1, which enhances PI3K signalling by inhibiting Pten expression 6, 16 . These data support the existence of selective pressure for resistant T-ALLs to retain Hes1 expression, even as they downregulated other Notch1 target genes (Fig. 3b) . We reasoned that outgrowth of leukaemic clones lacking NICD might reflect additional inhibitory crosstalk between these two oncogenic pathways. To address this question, we first investigated whether reducing Notch1 activity modulates PI3K signalling in cell lines without PTEN expression. Indeed, exposing PTEN-deficient cell lines to compound E induced Akt phosphorylation (Fig. 4e) . This response was not observed in BW, a T-ALL cell line lacking NICD expression (Fig. 4e) , and was variable in T-ALL cell lines with intact PTEN expression (Extended Data Fig. 7a, b) . The reciprocal experiment of pharmacologically inhibiting PI3K signalling did not alter NICD expression (Extended Data Fig. 7c) .
We next modulated Notch pathway activation in Jurkat T-ALL cells to assess the effects on GDC-0941 responses. Enforced expression of NICD enhanced sensitivity to GDC-0941 (Fig. 4f) , which was also true in several other T-ALL cell lines (Extended Data Fig. 7d ). By contrast, expressing a dominant-negative Mastermind protein (dnMAML) that blocks Notch1 transcriptional activity conferred resistance to GDC-0941 and increased pAkt levels (Fig. 4f, g ). Consistent with these data, exposing Jurkat cells to 0.1 mM of compound E, which inhibits NICD but does not alter proliferation, antagonized GDC-0941-mediated growth inhibition (Extended Data Fig. 7e, f) . Importantly, exogenous NICD expression abrogated the ability of compound E to induce resistance to GDC-0941 (Extended Data Fig. 7g ).
Discussion
To our knowledge, this is the first example in which in vivo treatment with a targeted anticancer agent selected for resistant clones lacking activation of a major oncogenic pathway involved in tumorigenesis (Fig. 4h) . Parental leukaemias expressing NICD activate Myc and other Notch1 target genes (Fig. 4h, left) . Many of these aggressive cancers respond to GDC-0941-either as a single agent or in combination with a MEK inhibitor. However, all ultimately develop drug resistance, which is frequently 1.2 −1.4 −1.4 −1.7 −1.0 −1.3 −1.2 −1.4 −1.1 −1.4 −1.4 −1.8 1.1 −1.6 −1.1 −1.4 −1.1 −1.4 −1.6 −1.5 1.1 −4.4 −1.5 −1.3 Max. proliferation (%) 
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characterized by loss of NICD expression and enhanced activation of the PI3K/Akt/S6 signalling pathway (Fig. 4h, right) . Biochemical and transcriptional downregulation of Notch1 signalling occurred in over 60% of resistant T-ALLs. The late acquisition of Notch1 mutations in murine T-ALLs 11,12 is consistent with human studies showing that NOTCH1 mutations are frequently cooperating events that may be absent at relapse 17 . Similarly, this RIM model accurately recapitulates the branched clonal architecture observed in relapsed human leukaemia 18 , as resistant T-ALLs isolated after in vivo drug treatment invariably shared multiple retroviral insertions with the corresponding parental T-ALL (Fig. 2d) . In some instances, isolating the same resistant T-ALL from multiple independent recipient mice provided compelling evidence for treatmentinduced selection of a pre-existing clone (Fig. 2d) . However, MOL4070LTR is a replication competent retrovirus and new integrations might also contribute to resistance.
We show that resistant T-ALLs restore activated PI3K/Akt signalling, but remain sensitive to high concentrations of GDC-0941. This paradigm of 'on pathway' but 'off target' resistance has been observed in advanced human cancers that recurred after treatment with tyrosine kinase inhibitors. For example, melanomas treated with Braf kinase inhibitors deploy multiple genetic mechanisms to reactivate Raf/MEK/ERK signalling (reviewed in ref. 19 ). It is therefore theoretically possible that more potent or selective PI3K inhibitors could overcome acquired resistance in T-ALL. However, we administered GDC-0941 at the MTD, and deeper target inhibition might not be feasible owing to toxicity to normal tissues.
Resistant T-ALL cells downregulated Myc expression. As Myc directly binds and positively regulates the PTEN promoter in T-ALL 6 , loss of Myc expression might facilitate the outgrowth of GDC-0941-resistant cells through this mechanism. However, PTEN/Pten-negative T-ALL cell lines increased pAkt levels in response to compound E, which infers the existence of PTEN-independent inhibitory crosstalk between the Notch1 and PI3K/Akt pathways. This idea is consistent with a recent report showing that Notch1 inhibits Akt activation by enhancing association with the PP2A phosphatase in Jurkat cells 20 . Furthermore, enforced expression of Myc did not recapitulate the enhanced sensitivity to GDC-0941 induced by NICD (Fig. 4f and Extended Data Fig. 7d ; data not shown). While it is unclear how resistant T-ALL cells compensate for loss of Myc expression, Pten loss or Akt activation overcomes the adverse effects of Myc withdrawal in a zebrafish model of T-ALL 21 . The unexpected observation that elevated NICD and Myc expression is dispensable for T-ALL growth in vivo might partially underlie the disappointing clinical efficacy of GSIs observed to date 22 . GDC-0941 prolongs the survival of recipient mice transplanted with primary T-ALL cells and drives clonal evolution in vivo, thereby validating PI3K as a therapeutic target in this aggressive cancer. Together with a recent study implicating PI3K signalling in resistance to glucocorticoids 5 , our data strongly support evaluating PI3K inhibition in T-ALL in combination with other anti-leukaemia agents. RAS mutations are commonly detected in early T-cell precursor ALL, an aggressive paediatric leukaemia with a high rate of treatment failure 23 , and a recent study implicated NRAS mutations in T-ALL relapse 24 . We identified oncogenic Kras mutations as a biomarker of resistance to GDC-0941 mono-therapy, and provide evidence that combining PI3K and MEK inhibitors might be beneficial in these challenging patients. Simultaneously targeting the NOTCH1 and PI3K/AKT pathways is a rational therapeutic approach in T-ALL 6, 25 . Importantly, however, our data suggest that combination regimens might inadvertently undermine the efficacy of PI3K inhibitors by facilitating the survival and outgrowth of drug resistant clones. Given this, sequential treatment with a NOTCH1 pathway inhibitor to suppress NOTCH1 mutant clones found at diagnosis followed by PI3K/AKT inhibition is an appealing approach. Finally, 
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whereas the NOTCH1 mutations found in T-ALL constitutively increase NOTCH1 signalling, inactivating mutations are implicated as 'drivers' in other human cancers 26 . Our studies therefore raise the provocative possibility that these loss-of-function NOTCH1 mutations contribute to tumorigenesis by aberrantly activating PI3K signalling.
METHODS SUMMARY
GDC-0941 was provided by Genentech and synthesized as previously described 14 . Compound E was purchased from Calbiochem. The PD0325901 used in these studies was synthesized by Shanghai Chempartner. All drugs were diluted in dimethylsulphoxide (DMSO) for in vitro studies. To generate resistant cell lines, the E2 line was plated in 0.5 mM GDC-0941 in six individual wells. As the cells became confluent, they were passaged and the GDC-0941 dose was increased to generate resistant clones E2-R3, E2-R5 and E2-R6, all of which grow in lymphocyte growth medium (LGM) containing 60 mM GDC-0941. The Notch1 gene was amplified using primers 59-A TAGCATGATGGGGCCACTA-39 and 59-CTCTGGAATGTGGGTGATCTGG-39 as previously described 11 . Southern blotting and cloning of retroviral insertions were performed as described elsewhere 11 . PCR products were sequenced by Quintara, and retroviral sequence tags were aligned against the University of California, Santa Cruz (UCSC) mm9 mouse reference genome assembly. All animal experiments conformed to national regulatory standards and were approved by the UCSF Committee on Animal Research. For T-ALL transplantation, 2 3 10 6 cells were injected retroorbitally into male 8-12-week-old sublethally irradiated congenic recipient mice. For pharmacokinetic and pharmacodynamic studies, plasma was isolated from blood and the concentrations of GDC-00941 in each plasma sample were determined by a non-validated liquid chromatography/mass spectrometry/mass spectrometry (LC/ MS/MS) assay as previously described 14 . Total Akt and pAkt S473 were measured by the Multi-Spot Detection System (Meso Scale Discovery). For preclinical testing, recipient mice were randomly assigned to receive control vehicle (0.5% hydroxypropyl methylcellulose and 0.2% Tween 80), GDC-0941 as a single agent, or GDC-0941 combined with PD0325901. We performed gene expression profiling on 28 independent parental and resistant mouse T-ALL tumours (Extended Data Table 3) using Affymetrix GeneChip HT MG-430 PM Affymetrix microarrays according to the manufacturer's instructions.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Plasmids. pRIEN (a gift from J. Zuber and S. Lowe) was used to introduce the ecotropic receptor into human cell lines to enable efficient retroviral infection and is Neo-resistant version of pRIEP 27 . MIG (MSCV-IRES-GFP) is the murine stem cell virus (MSCV) vector containing a green fluorescent protein (GFP) cassette driven by an internal ribosome entry site (IRES) 28 . MIG-NICD 29 and MSCV-dnMAMLeGFP 30, 31 have been described previously. Cell culture. T-ALL cell line E2 (ref. 12) was maintained in lymphocyte growth medium (LGM; DME, 20% FBS, 10 mM HEPES, penicillin/streptomycin, L-glutamine, non-essential amino acids, sodium pyruvate, 50 mM b-mercaptoethanol, 10 ng ml 21 IL-2, and 10 ng ml 21 IL-7). Cell lines BW (BW5147.3; #TIB-47), S1A (S1A.TB.4.8.2; #TIB-27), WEHI (WEHI7.1; #TIB-53), TIMI (TIMI.4; #TIB-37) and R1.1 (#TIB-42) were purchased from ATCC. T-ALL 7 and T-ALL 12 cell lines have been described before 12 . Jurkat cells were stably infected with pRIEN to allow retroviral infection. RIEN-expressing Jurkat cells were infected with MIG, MIG-NICD or MSCVdnMAML-eGFP and sorted for GFP. All cell lines were grown and maintained as recommended by ATCC and tested every 6 months for mycoplasma. Cell line drug escalation. The E2 cell line was plated in 0.5 mM GDC-0941 in six individual wells. As cells became confluent, they were passaged and the GDC-0941 dose was increased to generate resistant clones E2-R3, E2-R5 and E2-R6, all of which grow in LGM containing 60 mM GDC-0941. Proliferation assays. For cell line proliferation assays, 3-5 3 10 5 cells per well were grown in LCM in 24-well per plate format. Drugs suspended in DMSO or an equal volume of DMSO only (vehicle control) was added to each well. After a minimum of four cell doublings in vehicle wells, the cells were harvested and counted on a ViCell XR (Beckman-Coulter). For proliferation assays of T-ALL cell lines infected with MSCV-GFP viruses. GFP-positive and GFP-negative cells were co-cultured and proliferation assays were performed to compare the effects of drug treatment on each population. The cells were collected 72 h after infection and proliferation was assessed as described earlier except live cells were counted by flow cytometry using 7-ADD exclusion and CountBright absolute counting beads (Invitrogen).
For primary T-ALL proliferation assays, 2.5-5 3 10 5 cells per well were plated in triplicate in a 96-well plate. After 48 h, cell number was assayed using CellTiter 96 MTS reagent (Promega). For Jurkat combination assays, 1 3 10 4 cells were plated in triplicate and MTS activity was assayed at 72 h. Western blot analysis. Cells were lysed in RIPA buffer containing Complete Protease Inhibitor Cocktail (Roche). Anti-GFP antibody was from Santa Cruz Biotechnology (8334). All other antibodies were from Cell Signalling Technologies: pAkt S473 (4060), pAkt T308 (2965), Akt (9272), pErk (4370), pS6 (2211), PTEN (9552), NICD (4147), cMyc (5605) and actin (4967). Genetic analysis of T-ALL cells. Genomic DNA was digested with HindIII, followed by electrophoresis, and capillary transfer to Hybond-N filters (Amersham). Filters were hybridized with a MOL4070 LTR probe that was labelled with radioactive a-dCTP using Rediprime II (Amersham). For Notch1 mutation analysis, genomic DNA was amplified using primers 59-ATAGCATGATGGGGCCACTA-39 and 59-CTCTGGAATGTGGGTGATCTGG-39, which spans part of exon 34 of Notch1 as previously described 11 . Retroviral integrations were cloned using a 'shotgun' strategy exactly as described elsewhere 11 . The PCR products were sequenced by Quintara, and sequence tags were aligned against the mouse reference genome assembly. First, we demanded that sequence tags have the valid LTR sequence of MOL4070 virus using cross_match (http://www.phrap.org). Then, we trimmed the virus sequence from the sequence tags, and aligned them against the mouse reference genome (University of California, Santa Cruz (UCSC) mm9 assembly) using BLAT 32 . We used sequence tags aligned to the reference genome with .90% identify and .90% coverage. The tags aligned to multiple genomic loci with nearly identical alignment scores were discarded as tags with non-unique alignment. Finally, we obtained independent virus insertion loci by consolidating the tags supporting the same integration sites. We used the number of supporting tags for each independent locus as an indicator of the virus insertion sites in the tumour cell population. Mice. All animal experiments conformed to national regulatory standards and were approved by the UCSF Committee on Animal Research. For adoptive transfer of acute leukaemias, 2 3 10 6 cells were injected retro-orbitally into 8-12-week-old wild-type male C57Bl6/129Sv F1 (FBV) recipient mice that had been irradiated with 450 cGy. Pharmacokinetics and pharmacodynamics. For pharmacokinetic measurements, FVB mice were treated with a single dose of GDC-0941 and blood collected was at 0.5, 1, 2, 4, 8, 12 and 24 h post-dose by cardiac puncture. Plasma was isolated from blood and the concentrations of GDC-0941 in each plasma sample were determined by a non-validated liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) assay in the Drug Metabolism and Pharmacokinetics (DMPK) Department at Genentech as previously described 14 . The assay lower limit of quantitation (LLOQ) was 0.005 mM. For pharmacodynamic measurement, bone marrow from a single mouse was harvested in DME media containing 1% BSA and treated with varying concentrations of GDC-0941 for 15 min before stimulation with 10 ng ml 21 GM-CSF for 10 min. Cell lysates were prepared by homogenization in cell extraction buffer (Invitrogen), containing 10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 1% Triton X-100, 10% glycerol, 0.1% SDS and 0.5% deoxycholate supplemented with phosphatase and protease inhibitors (Sigma). Levels of total Akt, Akt phosphorylated at serine 473 (pAkt) were measured by The Meso Scale Discovery Multi-Spot Biomarker Detection System (Meso Scale Discovery). Phosphorylated proteins were normalized to total protein levels in GDC-0941-treated samples and compared to vehicle controls. Preclinical trials. In the single agent trial, recipient mice were randomly assigned to receive GDC-0941 at a dose of 125 mg kg 21 day 21 by oral gavage or a control vehicle (0.5% hydroxypropyl methylcellulose and 0.2% Tween 80). For combination treatment, mice received 100 mg kg 21 day 21 of GDC-0941 daily and PD0325901 was administered by oral gavage at a dose of 5 mg kg 21 day 21 4 days per week. Blinding was not feasible for these trials. Mice were observed daily during 8 weeks of treatment and weighed weekly to adjust the dose. On the basis of criteria established before initiating treatment, mice that died from causes other than leukaemia (diagnosed based on haematological findings that included elevated white blood cell count, splenomegaly and lymphoblasts in the bone marrow) were censored. The time to death in recipient mice transplanted with the same primary leukaemias typically varies by ,10%. This observation and previous work 13 established a sample size of five drug-treated and three vehicle-treated mice per leukaemia as having adequate statistical power to detect differences $50% in survival. To reflect the genetic heterogeneity present in the RIM system and in human leukaemia, we treated .20 individual Kras WT and Kras G12D leukaemias in over 250 individual mice that were randomly assigned to receive either control vehicle or drug treatment. Expression profiling and informatics. Twenty-eight mouse T-ALL tumours (Extended Data Table 3 ) were stained for CD4-and/or CD8-positive cells as described below and sorted on a FACSAriaIII (BD Biosciences). We performed gene expression profiling using Affymetrix GeneChip HT MG-430 PM Affymetrix microarrays according to the manufacturer's instructions. Signals from all samples were normalized using the Robust Multichip Average (RMA) algorithm implemented in Bioconductor R package 33 . Differential expression analysis was performed pairwise between all 'parental' and 'resistant' samples within each leukaemia (2M, 20M, and so on). When two parental samples were available, resistant clones were compared independently to each, resulting in a total of 25 comparisons representing 17 unique resistant leukaemias. Fold change was calculated as the ratio of the gene expression of the two samples and a heatmap of expression fold change on Notch1 target genes was generated in R for visualization. Immunophenotyping. Staining was carried out in FACS Staining Buffer (PBS with 2% heat inactivated FCS). Primary leukaemia cells were stained with APC or PE anti-CD4 (clone GK1.5) and PE or PECy7 anti-CD8 (clone 53-6.7) antibodies (eBiosciences) for 20 min, washed twice and analysed by flow cytometry using a FACSAriaIII or LSRII with FACSDiva software (BD Biosciences). Data were analysed using FlowJo software (TreeStar). Cell cycle analysis. For in vivo labelling, mice were dosed with drug and 4 h later BrdU (1 mg per 10 g) was administered by intraperitoneal injection and allowed to incorporate for 2 h. Cells were harvested and stained with FITC anti-CD4 and anti-CD8 antibodies before BrdU staining. Cell lines were plated in DMEM containing 10% FBS and drug for 16 h then 10 mM BrdU was added to the culture media and allowed to incorporate for 90 min. Staining with a V450-conjugated anti-BrdU antibody (clone 3D4) and 7-AAD was performed using a BrdU Flow Kit (BD Biosciences). Apoptosis assays. Primary T-ALL cells were harvested from mice and plated in LGM containing drug for 8 h. Cell lines were plated in DMEM containing 10% FBS and drug for 18 h. Cellular staining with a V450-conjugated anti-cleaved caspase 3 antibody (C92-605) was performed using a Cleaved Caspase Flow Kit (BD Biosciences). Statistics. Two-sided t-test was used to evaluate differences between conditions and a normal distribution of data points around the mean was assumed based on the use of isogenic cell lines and genetically identical leukaemias in all experiments. Error bars representing s.e.m. indicate variation for each group and variance was found to be similar between compared groups. Log-rank analysis was used to evaluate differences in Kaplan-Meier survival curves. and GFP 2 cells (blue line) were counted by flow cytometry and equalized to DMSO control (% maximum). e, Exposing Jurkat cells to 0.1 or 1.0 mM compound E for 24 h resulted in a dose dependent reduction in NICD protein levels. f, Jurkat cells were exposed to a range of GDC-0941 concentrations with 0.1 mM compound E or control vehicle (DMSO) for 72 h and proliferation was measured by MTS assay. The addition of compound E significantly reduced the efficacy of GDC-0941 at multiple concentrations. g, Stable Jurkat clones expressing either control vector (MIG) or NICD were treated with GDC-0941 and compound E according to the same protocol in f. Note that enforced expression of NICD rescues the compound E-mediated growth inhibition. f, g, Error bars show s.e.m. of three technical replicates. Asterisks indicate significant differences (two-sided t-test, P values , 0.05).
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